Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.
Bristol-Myers Squibb’s (BMS) chief scientific officer Francis Cuss is to step down following the company's huge lung cancer setback with Opdivo last year, to be replaced by former Massachus
